ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1466

The Effects of Rituximab and B-Cells Depletion on the Inflammatory and Pro-Thrombotic Profile of Leucocytes of Rheumatoid Arthritis Patients and on the Vascular Endothelium

Irene Cecchi1, Carlos Perez-Sanchez2, Patricia Ruiz-Limon3, Ivan Arias de la Rosa3, Maria Carmen Abalos-Aguilera3, Yolanda Jiménez-Gómez2, Rafaela Ortega-Castro2, Eduardo Collantes-Estévez2, Alejandro Escudero-Contreras3, Massimo Radin4, Nuria Barbarroja2, Dario Roccatello5, Savino Sciascia6 and Chary Lopez-Pedrera7, 1Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 2Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 3Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 4Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 5Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 6Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, 7IMIBIC/Reina Sofia Hospital/ University of Cordoba, Cordoba, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoimmune diseases, B cells, rheumatoid arthritis (RA) and rituximab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster II: Prognostic Factors, Imaging and Miscellaneous Reports

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Cardiovascular disease (CVD) constitutes a relevant cause of morbidity and mortality in Rheumatoid Arthritis (RA) patients. Rituximab (RTX) has been proved to be effective in the treatment of RA, indicating that B-cells play a crucial role in the pathogenesis of the disease, not only through the production of autoantibodies. Moreover, B-cells seem to be important in the development of CVD. However, the effect of RTX in the context of CVD in RA patients has not been fully elucidated yet.Therefore, the aims of this study were to evaluate the mechanism of action of RTX on immune and endothelial cells and to investigate the effect of B-cells depletion in the context of CVD in RA patients.

Methods: The analysis includes 10 RA patients with moderate-high disease activity based on Disease Activity Score using 28 joints. To evaluate the influence of B-cells depletion on the inflammatory profile of T-cells, purified lymphocytes from 6 RA patients were treated with RTX (1µg/ml) for 24 hours. B-cells depletion was assessed by flow cytometry and the changes in the inflammatory profile were analyzed by RT-PCR. Following, to identify changes in the activity of crucial mediators in the production of pro-inflammatory cytokines, a western blot was performed on extracted proteins from purified lymphocytes of the 6 RA patients treated with RTX. In a second set of experiments, supernatant from cultured lymphocytes of 6 RA patients, in the presence or in the absence of RTX, was added to cultured endothelial cells (HUVECs) and monocytes isolated from Healthy Donors (HDs) and the response was analyzed by RT-PCR. Finally, serum from 4 RA patients at baseline and after 3 months of therapy with RTX, was added to HUVECs and monocytes isolated from HDs and the response was analyzed by RT-PCR.

Results: In parallel to a significant depletion of B-cells, we observed a downregulation of the pro-inflammatory profile of T-lymphocytes, as shown by a significant drop of IL1, IL6, IL17, IFNγ, and TNFα genes expression levels. We also found a decrease in the phosphorylation and protein expression of STAT-3 and p38 in lymphocytes treated with RTX, compared to non-treated T-cells. HUVECs and monocytes cultured with supernatant of RA-lymphocytes treated with RTX, showed a decrease in the expression levels of various pro-thrombotic factors (i.e. TF, IL8, and VEGF) as well as cell-adhesion molecules (i.e. V-CAM, I-CAM and e-Selectin). Both HUVECs and monocytes, treated with serum of RA patients after 3 months of therapy with RTX, showed a reduced expression of genes related to their pro-thrombotic and pro-inflammatory profile.

Conclusion: Overall, RTX showed a beneficial effect in the context of CVD in RA patients, through the modulation of the inflammatory and pro-thrombotic profile of distinct leukocytes subtypes and vascular endothelial cells. Supported by CTS-794, ISCIII (PI15/01333; RIER RD16/0012/0015)


Disclosure: I. Cecchi, None; C. Perez-Sanchez, None; P. Ruiz-Limon, None; I. Arias de la Rosa, None; M. C. Abalos-Aguilera, None; Y. Jiménez-Gómez, None; R. Ortega-Castro, None; E. Collantes-Estévez, None; A. Escudero-Contreras, None; M. Radin, None; N. Barbarroja, None; D. Roccatello, None; S. Sciascia, None; C. Lopez-Pedrera, EFPIA, 2.

To cite this abstract in AMA style:

Cecchi I, Perez-Sanchez C, Ruiz-Limon P, Arias de la Rosa I, Abalos-Aguilera MC, Jiménez-Gómez Y, Ortega-Castro R, Collantes-Estévez E, Escudero-Contreras A, Radin M, Barbarroja N, Roccatello D, Sciascia S, Lopez-Pedrera C. The Effects of Rituximab and B-Cells Depletion on the Inflammatory and Pro-Thrombotic Profile of Leucocytes of Rheumatoid Arthritis Patients and on the Vascular Endothelium [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-effects-of-rituximab-and-b-cells-depletion-on-the-inflammatory-and-pro-thrombotic-profile-of-leucocytes-of-rheumatoid-arthritis-patients-and-on-the-vascular-endothelium/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effects-of-rituximab-and-b-cells-depletion-on-the-inflammatory-and-pro-thrombotic-profile-of-leucocytes-of-rheumatoid-arthritis-patients-and-on-the-vascular-endothelium/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology